J&J Buys Eye-Drug Biotech Ollin for $3.3 Billion: Terms, Drug & Impact
Johnson & Johnson will pay $2.2 billion upfront, up to $3.3 billion in all, for Ollin Biosciences and its Phase 3 eye drug OLN324 for wet AMD.
Image: Wikimedia Commons / user:ekem
NEW BRUNSWICK, N.J., Nov. 16 — Johnson & Johnson said on Monday it has agreed to acquire Ollin Biosciences, a Texas-based clinical-stage biotechnology company, for $2.2 billion upfront, with milestone payments that could lift the total price to about $3.33 billion. The deal hands J&J a late-stage experimental eye drug, OLN324, and a new position in treatments for retinal diseases that cause vision loss.
The acquisition, announced by Johnson & Johnson in a statement on Monday, centres on OLN324, an investigational bispecific antibody in Phase 3 trials for wet age-related macular degeneration and diabetic macular edema. The company said the deal is expected to close before the end of 2026, subject to regulatory approvals. Blackstone Life Sciences will pay $750 million to fully fund the Phase 3 trials.
Key Takeaways
- J&J will pay $2.2 billion upfront for Ollin, plus up to $1.125 billion in milestones, for a maximum of $3.33 billion.
- OLN324 is a Phase 3 antibody targeting VEGF and Ang2, for wet AMD and diabetic macular edema, which affect more than 40 million people.
- Blackstone Life Sciences will pay $750 million to fully fund the Phase 3 trials, for milestone payments and single-digit royalties.
- Eli Lilly agreed the same day to buy Calytrix Bio for up to $1.5 billion, taking its 2026 spending past $32 billion.
What Is OLN324 and Which Eye Diseases Does It Treat?
OLN324 is designed to block two proteins that drive retinal disease: vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). Wet AMD happens when abnormal blood vessels grow beneath the retina and leak fluid or blood. Diabetic macular edema happens when diabetes damages small blood vessels in the retina and fluid collects in the macula. Both are leading causes of vision loss, and Johnson & Johnson said they affect more than 40 million people worldwide. Roche's Vabysmo and Regeneron's Eylea dominate the market today.
J&J-Ollin Deal Terms: $2.2 Billion Upfront, $750 Million From Blackstone
Most of the headline price is not guaranteed. Johnson & Johnson will pay $2.2 billion in cash when the deal closes, and the remaining $1.125 billion will be paid only if OLN324 clears regulatory and commercial milestones. Reports before the announcement had put the total at up to $3.4 billion.
| Deal term | Detail |
|---|---|
| Upfront cash payment | $2.2 billion |
| Milestone payments | Up to $1.125 billion |
| Maximum total value | About $3.33 billion |
| Blackstone Phase 3 funding | $750 million over several years |
| Expected close | Before the end of 2026 |
Blackstone will pay the $750 million to Johnson & Johnson over several years to cover the full cost of the Phase 3 programme, receiving milestone payments and single-digit royalties on sales if the drug succeeds.
Eli Lilly's $1.5 Billion Calytrix Deal and the 2026 Biotech Buying Spree
Eli Lilly agreed on Monday to acquire Calytrix Bio, a biotechnology company based in Wellesley, Massachusetts, for up to $1.5 billion in cash, to expand its work on treatments for rare blood cancers. Calytrix's lead asset is a preclinical antibody for mutant calreticulin-driven essential thrombocythemia and myelofibrosis, two rare blood cancers. The upfront payment was not disclosed, and the antibody has not yet been tested in people. The deal takes Lilly's 2026 acquisition spending past $32 billion.
Frequently Asked Questions
How much is Johnson & Johnson paying for Ollin Biosciences?
Johnson & Johnson will pay $2.2 billion upfront, with up to $1.125 billion more in milestone payments, for a maximum of about $3.33 billion. The deal is expected to close before the end of 2026.
What is OLN324 and when could it reach patients?
OLN324 is an investigational bispecific antibody in Phase 3 trials for wet AMD and diabetic macular edema. It has not yet been approved by the U.S. Food and Drug Administration, and Johnson & Johnson has not given a date for a filing.
What are wet AMD and diabetic macular edema?
Wet AMD happens when abnormal blood vessels grow under the retina and leak fluid. Diabetic macular edema is a diabetes complication in which damaged retinal vessels leak fluid into the macula. Both cause vision loss and affect more than 40 million people worldwide.
Is Eli Lilly also buying a biotech company?
Yes. Eli Lilly agreed on Monday to acquire Calytrix Bio for up to $1.5 billion in cash, adding a preclinical antibody for rare blood cancers called myeloproliferative neoplasms. The deal takes Lilly's 2026 acquisition spending past $32 billion.
Johnson & Johnson expects the deal to close before the end of 2026.